BOEHRINGER SEEKS TO ENJOIN LIFESCAN FROM MAKING GLUCOSE MONITORS BASED ON ACCUTREND DM TECHNOLOGY; SUIT CHARGES J&J UNIT WITH INDUSTRIAL ESPIONAGE
This article was originally published in The Gray Sheet
Executive Summary
Boehringer Mannheim Corporation is seeking to enjoin Johnson & Johnson's LifeScan subsidiary from selling blood glucose monitors that incorporate technology from its Accutrend DM monitor. In a suit filed June 19 in the U.S. District Court in Indianapolis, Boehringer alleges that LifeScan illegally obtained information on the monitor through industrial espionage and should be barred "from marketing any products based on the information for a period of time equal to that it would have taken LifeScan and [J&J] to develop those products independently."